SDS. Yu. Davidian

S. Yu. Davidian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. Yu. Davidian has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the utility of hematological indices in monitoring rheumatoid arthritis activity in patients receiving treatment with the direct interleukin 6 inhibitor olokizumab

    by M. A. Korolev, D. A. Yudina, S. Yu. Davidyan, A. Yu. Doroshevskaya, A. V. Makevnina, L. B. Pak, I. G. Bannikova, K. P. Morozova, E. V. Kalinina, E. A. Bogdanova, et al.

    Hematological indices (HIs) are informative, cost-effective, and easy-to-calculate markers for monitoring rheumatoid arthritis (RA) activity. Objective : to analyze the utility of the following hematological indices: neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for monitoring RA activity in patients receiving treatment with the direct interleukin (IL) 6 inhibitor olokizumab (OKZ). Material and methods . The study included 866 patients with RA who initiated OKZ therapy in 2023–2024 and continued treatment for at least 12 months. RA activity parameters, including DAS28-CRP, CDAI, ESR, CRP, NLR, and PLR, were assessed at baseline and at 3, 6, and 12 months after initiation of OKZ therapy. Statistical analysis was performed using generally accepted nonparametric methods. Differences were considered statistically significant at pResults and discussion . At baseline, a lower NLR value was associated with female sex, shorter RA duration, lower ESR and CRP levels, and a reduced need for glucocorticoids (GCs). A lower baseline PLR value was associated with lower ESR and CRP levels and lower DAS28-CRP and CDAI values. A reduction in NLR during the first 3 months of OKZ therapy was associated with achieving remission by month 6 (DAS28-CRP: odds ratio 1.20; 95% confidence interval 1.07–1.35; p=0.002). Lower baseline NLR levels reflected the possibility of more rapid GC withdrawal. OKZ treatment resulted in neutropenia in 2.3% of cases and thrombocytopenia in 3.1%; these events were mild and did not require discontinuation of OKZ. Conclusion. The findings confirm the utility of HIs in assessing RA activity. Changes in NLR at the beginning of OKZ therapy may be considered a predictor of achieving remission/low disease activity, as well as of the possibility of GC withdrawal in patients with RA.

  • Open Access

    Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: Two-year results of the real word evidence LIBRA study

    by Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Yu. Davidian, O. E. Epifanova, N. A. Kiryukhina, L. V. Masneva, et al.

    Under real-world clinical practice together with indices for assessing disease activity and the effectiveness of therapy, drug retention provides critical information on efficacy, safety, compliance and convenience of use.The aim – to obtain data on the safety of netakimab (NTK) in a population of patients with ankylosing spondylitis (AS), including various somatic diseases, as well as to assess retention on therapy during 2 years of observation in real word clinical practice.Materials and methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included 137 patients who were prescribed netakimab therapy before enrollment. Clinical and medical history data for the first visit were entered retrospectively, and following visits at 12, 24, 52, 76, 104 weeks of therapy were collected within the study. The average age of the patients 42,3 y. O., 34.3% of them with previous biologics therapy.Results. Median observation period was 104 weeks (range 1–137 weeks). At the end of the analyzed period (104 weeks of therapy), 85,5% [95% confidence interval (95% CI): 79.7–91.8] of patients continued treatment with Netakimab. Retention on NTK therapy was slightly better in “bio-naïve” vs patients who received biologics earlier: 88.7% (95% CI: 82.3–95.5) and 78.9% (95% CI: 67.5–92.2), respectively, without significant differences between groups (p=0.16). 21 (15.3%) patients withdrew from study before visit 6. The main end of study reasons was lost to follow-up – 7 (5.1%) patients, and treatment inefficacy – 6 (4.4%) patients. The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein) showed statistically significant decreases from baseline: by three times during the first 3 months of therapy and two times decrease during the first year of treatment. This trend continued in the second year of treatment, although with a lower rate of reduction. By week 104 of therapy, 52.9% (95% CI: 47.3–58.4) reached low disease activity (1.3≤ASDASConclusions. In real-world clinical practice, 85.5% of patients continued treatment with Netakimab at the end of 104 weeks. By 104 weeks 74% patients had low disease activity or inactive disease. Netakimab was well tolerated by most of patients.


  • Open Access

    Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

    by P. A. Shesternya, A. I. Zagrebneva, O. V. Antipova, Yu. V. Arbuzova, I. G. Bannikova, L. V. Belozertseva, E. A. Bogdanova, S. A. Bykova, E. A. Vasilenko, I. B. Vinogradova, et al.

    Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.


  • Open Access

    Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study

    by A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, М. Л. Гольдман, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, et al.

    The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of LVL in RA patients.   Objective: to evaluate the efficacy and safety of LVL in the treatment of patients with RA in real-world clinical practice.   Materials and methods. The HELIOS study is a retrospective-prospective, multicenter, non-interventional study of retention rate of LVL therapy and the safety of LVL in patients with RA in real-world clinical practice. Patients received medical care, including LVL, according to routine clinical practice for the treatment of RA and Russian instructions for medical use of the drug. This article presents the results of an analysis of the efficacy and safety of LVL after 12 and 24 weeks of treatment. Efficacy was assessed using the DAS28-CRP/ESR, SDAI, CDAI and patient assessment of pain, fatigue and morning stiffness according to VAS (0–100 mm).   Results and discussion. 524 patients from 42 medical centers in the Russian Federation were enrolled in the study from June 2022 to November 2023. The majority of patients were female (83.2 %) and the mean age of patients was 53 years. A statistically significant decrease in DAS28-CRP/ESR, SDAI, CDAI, patient assessment of pain, fatigue and morning stiffness (VAS) was observed after 12 and 24 weeks of treatment, regardless of previous treatment with biologics or Jak inhibitors (JAKi). LVL was well tolerated by patients, the most frequently reported adverse events were infections, changes in peripheral blood and laboratory abnormalities characteristic of treatment with IL-6R inhibitors.   Conclusion. In real-world clinical practice, LVL has been shown to be highly effective and well tolerated in patients with RA when prescribed as the first biologic disease-modifying antirheaumatic drus (bDMARD) and after switching from other bDMARDs or JAKi.


  • Open Access

    Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study

    by Sh. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Yu. Davidian, O. E. Epifanova, N. A. Kiryukhina, L. V. Masneva, et al.

    Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at weeks 12, 24 and 52 of therapy were collected within the study. Drug survival rate has been calculated according to Kaplan – Meier analysis.Results. The study included 137 patients (93 men and 14 women) with AS. The average age of patients was 42.3 (±11.9) years, 34.3% of patients had previously received therapy with genetically engineered biologic drugs, mainly tumor necrosis factor inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% [95% CI: 85.4–95.7] of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; adverse effects (AEs), related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. 2 patients stopped taking netakimab due to AEs: terminal ileitis and chronic colitis.Conclusions. In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.